The effective therapy of cyclosporine A with drug delivery system in experimental colitis

Journal of Drug Targeting

Volumn 19, Issue 6, 2011, Pages 458-467

  Fukata, Norimasa ^a   Uchida, Kazushige ^a   Kusuda, Takeo ^a   Koyabu, Masanori ^a   Miyoshi, Hideaki ^a   Fukui, Toshiro ^a   Matsushita, Mitsunobu ^a   Nishio, Akiyoshi ^a   Tabata, Yasuhiko ^b   Okazaki, Kazuichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

colitis; Cyclosporine A; dextran sulfate sodium; drug delivery system; inflammatory bowel disease; ulcerative colitis

Indexed keywords

CXCL1 CHEMOKINE; CYCLOSPORIN A; DEXTRAN SULFATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROSPHERE; MYELOPEROXIDASE; POLY(DEXTRO,LEVO LACTIC ACID); POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GENE EXPRESSION; HISTOPATHOLOGY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; COLITIS; CYCLOSPORINE; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROSPHERES; POLYMERS; TISSUE DISTRIBUTION;

EID: 79958846574     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.511224     Document Type: Article

References (46)

1. Aberra FN, Lichtenstein GR. (2005). Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther, 21, 307-319. (Pubitemid 40313935)
2. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. (1998). Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis, 4, 276-279. (Pubitemid 128699866)
3. Bendjelloul F, Mal P, Mandys V, Jirkovsk M, Prokesov L, Tuckov L, Tlaskalov Hogenov H. (2000). Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis. Clin Exp Immunol, 119, 57-63. (Pubitemid 30064591)
4. Bradley PP, Priebat DA, Christensen RD, Rothstein G. (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol, 78, 206-209. (Pubitemid 12171880)
5. Edwards FC, Truelove SC. (1963). The course and prognosis of ulcerative colitis. Gut, 4, 299-315.
6. Egesten A, Eliasson M, Olin AI, Erjeft JS, Bjartell A, Sangfelt P, Carlson M. (2007). The proinflammatory CXC-chemokines GROalpha/ CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis, 22, 1421-1427. (Pubitemid 47543330)
7. Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. (1995). Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol, 10, 387-395.
8. Haneda S, Fukushima K, Funayama Y, Shibata C, Takahashi K, Tabata Y, Sasaki I. (2007). A new drug delivery system targeting ileal epithelial cells induced electrogenic sodium absorption: possible promotion of intestinal adaptation. J Gastrointest Surg, 11, 568-577.
9. Hirotani T, Lee PY, Kuwata H, Yamamoto M, Matsumoto M, Kawase I, Akira S, Takeda K. (2005). The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol, 174, 3650-3657. (Pubitemid 40354075)
10. Jennings C, Kusler B, Jones PP. (2009). Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun, 15, 109-120.
11. Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Kitazume MT, Takayama T, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. (2009). Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J Immunol, 183, 1724-1731.
12. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. (2008). Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest, 118, 2269-2280. (Pubitemid 351872344)
13. Kim Y, Moon JS, Lee KS, Park SY, Cheong J, Kang HS, Lee HY, Kim HD. (2004). Ca2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. Biochem Biophys Res Commun, 314, 695-703. (Pubitemid 38112855)
14. Kornbluth A, Present DH, Lichtiger S, Hanauer S. (1997). Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol, 92, 1424-1428. (Pubitemid 27412859)
15. Kristensen NN, Brudzewsky D, Gad M, Claesson MH. (2006). Chemokines involved in protection from colitis by CD4+CD25+ regulatory T cells. Inflamm Bowel Dis, 12, 612-618. (Pubitemid 43977743)
16. Lee H, Ahn YT, Lee JH, Huh CS, Kim DH. (2009). Evaluation of anticolitic effect of lactic acid bacteria in mice by cDNA microarray analysis. Inflammation, 32, 379-386.
17. Lichtiger S. (2009). Treatment of choice for acute severe steroidrefractory ulcerative colitis is cyclosporine. Inflamm Bowel Dis, 15, 141-142.
18. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 330, 1841-1845. (Pubitemid 24188135)
19. Mahida YR. (2000). The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis, 6, 21-33.
20. Mihatsch MJ, Thiel G, Ryffel B. (1988). Histopathology of cyclosporine nephrotoxicity. Transplant Proc, 20, 759-771.
21. Moss AC, Peppercorn MA. (2008). Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs, 68, 1157-1167. (Pubitemid 351822109)
22. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, Chiba T. (2000). Development of an oral drug delivery system targeting immuneregulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther, 292, 15-21. (Pubitemid 30026351)
23. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. (2004). Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation, 78, 557-565 (Pubitemid 39097102)
24. Navazo L, Salata H, Morales S, Dorta MC, Pez F, de las Casas D, Avil J. (2001). Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol, 36, 610-614. (Pubitemid 32424252)
25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694-702. (Pubitemid 20069706)
26. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. (1994). Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut, 35, 669-674. (Pubitemid 24163796)
27. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. (1997). Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology, 112, 1493-1505. (Pubitemid 27181373)
28. Schenk M, Bouchon A, Seibold F, Mueller C. (2007). TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest, 117, 3097-3106. (Pubitemid 47529639)
29. Shibusawa Y, Negishi I, Tabata Y, Ishikawa O. (2008). Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly (L-lactic acid) microspheres. Rheumatology (Oxford), 47, 454-457.
30. Smith PD, Ochsenbauer-Jambor C, Smythies LE. (2005). Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev, 206, 149-159. (Pubitemid 41105168)
31. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. (2005). Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest, 115, 66-75. (Pubitemid 40385506)
32. Soriano-Izquierdo A, Gironella M, Massaguer A, Salas A, Gil F, Piqué JM, Pan J. (2004). Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis. Inflamm Bowel Dis, 10, 789-800. (Pubitemid 39545225)
33. Strestov P, Otov B, Filipec M, Masek K, Farghali H. (2001). Different mechanisms in inhibition of rat macrophage nitric oxide synthase expression by FK 506 and cyclosporin A. Immunopharmacol Immunotoxicol, 23, 67-74. (Pubitemid 32280755)
34. Tabata Y, Ikada Y. (1988). Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo-and copolymers. J Biomed Mater Res, 22, 837-858.
35. Tabata Y, Ikada Y. (1990a). Drug delivery systems for antitumor activation of macrophages. Crit Rev Ther Drug Carrier Syst, 7, 121-148 (Pubitemid 20381567)
36. Tabata Y, Ikada Y. (1990b). Macrophage activation for antitumour function by muramyl dipeptide-protein conjugates. J Pharm Pharmacol, 42, 13-19. (Pubitemid 20124190)
37. Tabata Y, Ikada Y. (1990c). Phagocytosis of polymer microspheres by macrophages. Advances in Polymer Science, 94, 107-141.
38. Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677-1685. (Pubitemid 27041922)
39. Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, Okazaki K, Yodoi J, Chiba T. (2006). Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology, 131, 1110-1121. (Pubitemid 44498706)
40. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. (2003). Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology, 125, 1025-1031. (Pubitemid 37193449)
41. Watanabe N, Ikuta K, Okazaki K, Nakase H, Tabata Y, Matsuura M, Tamaki H, Kawanami C, Honjo T, Chiba T. (2003). Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci, 48, 408-414. (Pubitemid 36233012)
42. Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. (2006). Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis, 12, 1131-1135. (Pubitemid 44847470)
43. Williams CM, Coleman JW. (1995). Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology, 86, 244-249.
44. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. (2001). Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology, 120, 925-937. (Pubitemid 32193189)
45. Winer J, Jung CK, Shackel I, Williams PM. (1999). Development and validation of real-time quantitative reverse transcriptasepolymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem, 270, 41-49. (Pubitemid 29230718)
46. Wolf BA, Daft MC, Koenig JW, Flye MW, Turk JW, Scott MG. (1989). Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H-or 125I-labeled ligand compared. Clin Chem, 35, 120-124. (Pubitemid 19046797)